New Enterprise Associates
http://www.nea.com/Home/New Enterprise Associates is a venture capital firm based in Baltimore, MD. The firm has backed more than 160 companies that have gone public and invested in more than 230 companies that have been successfully merged or acquired. NEA focuses its investments in the information technology, healthcare, and energy technology industries. While NEA makes a majority of its investments in the United States, the firm invests around the world in China and India. The firm was founded in 1978.
View Older Stories View More Recent Stories
-
MBX Biosciences to Participate in 42nd Annual J.P. Morgan Healthcare Conference
-
ACA Has Helped Cut Independent Worker Uninsured Rate Nearly in Half, Yet Many Remain Without Health Coverage Due to Perceived Unaffordability
-
VAST Data Closes Series E Funding Round, Nearly Triples Valuation to $9.1 Billion
-
VAST Data eyes IPO after valuation surges to $9.1 billion in latest fund raise
-
New Report Reveals that 83% of Companies are Prioritizing Product Integrations in 2024
-
SpyGlass Pharma Strengthens Leadership to Further Advance its Intraocular Drug Delivery Platform
-
Sara Nayeem, M.D., Experienced Biopharmaceutical Venture Investor, Joins Enavate Sciences as Executive Vice President, Investments
-
Smartcar and Uber Partner to Accelerate the Transition to Electric by Removing Range Anxiety for Drivers
-
Second Front Systems raises $40 million, led by NEA, to speed delivery of commercial software to global public sector
-
Form SC 13D Korro Bio, Inc. Filed by: New Enterprise Associates 17, L.P.
-
Care.com and Stride Team Up to Provide Caregivers Access to Health Insurance and Other Benefits
-
Stride Health Partners with Shipt to Offer Shoppers and Drivers Access to Affordable Health Insurance During Open Enrollment
-
MBX Biosciences to Participate in Piper Sandler 35th Annual Healthcare Conference
-
Revelle Aesthetics Receives First International Clearance in Australia for its Avéli® Cellulite Device
-
Myna Snacks Launches to Bring Health, Flavor, and Fun to Snacking in the Digital Age
-
Aigen's $12M Series A Unleashes True-Solar Agriculture Robots
-
LXA Raises US$10M in Seed Funding Round Led by NEA
-
Form 3 Korro Bio, Inc. For: Nov 03 Filed by: New Enterprise Associates 17, L.P.
-
AviadoBio Announces FDA IND Clearance and Fast Track Designation for AVB-101 for the Treatment of Frontotemporal Dementia with Progranulin (GRN) Mutations
-
Timescale Launches Dynamic PostgreSQL, the Cost-Effective Alternative to Serverless and Peak-Allocation Pay Models
-
MBX Biosciences Announces Appointment of Michelle Graham as Chief Human Resources Officer
-
MBX Biosciences to Participate in Stifel 2023 Healthcare Conference
-
Stride Health Kicks Off 2024 ACA Open Enrollment with New Plan Selection Experience and New Partners
-
Insurtech startup QuoteWell comes out of stealth, raised over $20M in Series A funding led by NEA
-
AviadoBio Announces Presentation of Promising Preclinical Safety and Biodistribution Data of its Gene Therapy Candidate AVB-101 for FTD-GRN at the Annual European Society of Gene and Cell Therapy Cong
-
Transfix Closes $40M Series F Funding Round Led by New Enterprise Associates and G Squared
-
Waymark Secures Additional $42M to Scale Tech-Enabled, Community-Based Care for Primary Care Providers and People Enrolled in Medicaid
-
MBX Biosciences Presents Positive Results from Phase 1 Study of MBX 2109 in Late-Breaking Oral Presentation at the American Society for Bone and Mineral Research Annual Meeting
-
Form SC 13D/A SYNLOGIC, INC. Filed by: New Enterprise Associates 14, L.P.
-
Mojo Vision Closes Successful New Series A Funding Round with $43.5M to Drive Micro-LED Development and Commercialization
-
Pair Eyewear Announces $75M Series C Funding Round As It Touts Revenue Growth And Enhanced Automated U.S. Manufacturing
-
AviadoBio Announces Initiation of Phase 1/2 Clinical Trial, ASPIRE-FTD, Evaluating AVB-101 in People with Frontotemporal Dementia with GRN Mutations
-
MBX Biosciences Doses First Participant in Phase 1/2 Clinical Trial of MBX 1416 for the Treatment of Post-Bariatric Hypoglycemia
-
MBX Biosciences to Showcase Results from Phase 1 Study of MBX 2109 in Late-Breaking Oral Presentation at the American Society for Bone and Mineral Research Annual Meeting
-
Form SC 13D/A Bright Health Group Inc. Filed by: New Enterprise Associates 15, L.P.
-
Non-Alcoholic Retailer Boisson Announces New CEO; Receives New Funding From Convivialité Ventures and Connect Ventures
-
Bright Health Group (BHG) Continues to Make Significant Progress Towards ACA Insurance Business Wind-Down
-
Bright Health Group Continues to Make Significant Progress Towards ACA Insurance Business Wind-Down
-
Hunt Scanlon Media to Host Private Equity and Venture Capital Recruiting Conference
-
MBX Biosciences Announces Positive Phase 1 Multiple Ascending Dose Data for MBX 2109, a Long-Acting Parathyroid Hormone Peptide Prodrug, in Healthy Adults
-
SafeBase Acquires Fellow Y Combinator-Backed Stacksi to Fuel Its Vision for Zero-friction Security Assessments
-
OncoResponse Announces Appointment of Carol Gallagher to Board of Directors
-
Revelle Aesthetics™ Brings Cellulite Education to the Forefront in Celebration of National Cellulite Day
-
Inventiva announces a financing of approximately €35.7 million from new and existing investors, consisting of a €30.6 million reserved capital increase and a €5.1 million issuance of royalty cer
-
Zeal Capital Partners Welcomes Former New Enterprise Associates Healthcare Investor, Emily Zhen, as Principal
-
MBX Biosciences to Participate in Morgan Stanley Global Healthcare Conference
-
Modyfi launches full public beta for AI design platform, announces $7M in seed funding led by NEA
-
Form SC 13D/A Bright Health Group Inc. Filed by: New Enterprise Associates 15, L.P.
-
Reimagined TechCrunch Disrupt 2023 Features New Stages and Return of Expanded Startup Battlefield Competition
-
MBX Biosciences Announces U.S. FDA Clearance of IND Application for MBX 1416 for the Treatment of Post-Bariatric Hypoglycemia

